IASLC The Great Debate Dr. Einhorn Dr. Simone And Dr. Florez
In this episode of Lung Cancer Considered, recorded at the 2023 Targeted Therapies of Lung Cancer meeting, host Dr. Narjust Florez moderates a conversation about the use of consolidated radiation in e...
21 Maalis 202317min
LCC Targeted Therapy Recap
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a recap of the recent IASLC meeting, Targeted Therapies for Lung Cancer, or TTLC23 --a member-favorite, a relatively smaller meeti...
9 Maalis 202338min
IASLC - Neoadjuvant
In this Virtual Tumor Board episode of Lung Cancer Considered, host Dr. Stephen Liu and his guests discuss the dynamic topic of managing resectable stage III NSCLC. Joining him are: Dr. Isabelle S...
7 Maalis 202345min
IASLC EGFR AM And PM
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on a specific subset of lung cancer: EGFR exon 20 insertion NSCLC. Joining the podcast are distinguished panel of cl...
23 Helmi 202339min
IASLC RET NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion about NSCLC with RET rearrangements, including diagnosis, treatment, and new exciting research coming down the pi...
22 Helmi 202334min
IASLC - KRAS G12C
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a conversation on KRAS G12C mutation. Joining the podcast are Dr. Melissa Johnson, the Program Director of Lung Cancer Research at...
21 Helmi 202333min
IASLC - LALCA Highlights
The Latin American Conference on Lung Cancer, held in Uruguay, wrapped up in late January. To provide a summary of key findings from the meeting, Lung Cancer Considered host Dr. Narjust Florez interv...
7 Helmi 202336min
IASLC FDA Approval Adjuvant Pembrolizumab For NSCLC
On January 26, 2023, the US FDA granted approval of pembrolizumab, an anti-PD-1 antibody, as an adjuvant therapy for patients with resected NSCLC. In this episode of Lung Cancer Considered host Dr. S...
2 Helmi 202330min
